Agimeteran a TLR7/8i 30 mg in #cutaneous #lupus which differentiated from placebo. Small single site #RCT. Far more pts improved #CLASI by 50% vs PBO #ACR23 #ACRbest ⁦@RheumNow⁩ ⁦@ACRheum⁩ L15 In larger RCT now! https://t.co/zssjgpydVY

Burden of flare & organ damage of SLE pts from the Asia Pacific cohort: Prevalence of organ damage at BL - 39% Incidence of damage accrual: ~58 per 1000PY Pts w/ >=2 flares accrued damage Flares independently⬆️risk of damage accrual #ACR23 ABST2261 @RheumNow @rheumarhyme https://t.co/nW34sI9FdP

#ACR23 Abstr#2332 We need to compliment the Complement #SLE. Post-hoc analysis of SOC + PBO from Dapirolizumab Phase 2 RCT showed reduced response in patients who flared with low complement levels vs normal or persistent activity. To consider as a stratifier @RheumNow https://t.co/BcN6ExLD0s

Treatment of lupus nephritis #ACR23 Dall’Era M, Furie R, Mosca M @RheumNow https://t.co/Md2DsOrY5F

Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY

Lupus Nephritis and the Target with PR3+ in proliferative classes with more aggresive phenotype.. #Lupus biopsy.. #ACR23 https://t.co/fGJX57hWx4

Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

• Dr. John Cush

Latest in Lupus Treatment at #ACR23 • Dr. Dall’Era & Dr. Furie • Approach to Lupus Nephritis 🫘 • Treating Non-Renal SLE / Skin #Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe

#Lupus #ACR23🦋 🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy 🔥Promising step towards future in revolutionizing Lupus T/t💡📑 💡Keeps efficacy of other vaccines intact! Follow this thread showcasing other imp findings #ACRambassador 1/2 https://t.co/aNFTmJiH0X